LONDON: Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION platforms, announced that AffyXell Therapeutics (“AffyXell”), a joint venture between Avacta and Daewoong Pharmaceutical (“Daewoong”), has entered into a collaboration agreement with Biocytogen, a Chinese company specializing in developing new biological…